Aeris Capital
VC Fund
Pfaffikon, Switzerland
Aeris Capital is a VC fund in Pfaffikon focused on Biotechnology and Medical. Aeris Capital AG is a private equity fund and financial advisor with locations in the United States and Switzerland.
- Total investments:
- 22
- Last investment:
- Lead investor:
- 27%
Last updated:
For AI agents: llms.txt
Industries Aeris Capital invests in
Stages Aeris Capital invests in
Countries Aeris Capital invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
4 more contacts available
Investment Focus
Industry
- Biotechnology 7 (32%)
- Medical 6 (27%)
- Health Care 6 (27%)
- Therapeutics 3 (14%)
- Mobile 2 (9%)
Stage
- Series A 5 (23%)
- Series D 5 (23%)
- Series C 4 (18%)
- Series B 3 (14%)
- Series E 2 (9%)
Country
- United States 8 (36%)
- Germany 2 (9%)
- Canada 1 (5%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
George Rehm
Managing Director
|
Managing Director | Total investments: 10 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Jiff
|
Jiff is a venture-backed, Mountain View-based technology company that is reinventing healthcare, one employee at a time. It builds customized mobile and web experiences that connect company benefits and incentives design to healthy employee behaviors using the wearables and apps that they all know and love.The company was founded in 2010 and isheadquartered in Mountain View, California. | $17.7M / Series C / Jun 07, 2016 | |
|
Jiff
|
Jiff is a venture-backed, Mountain View-based technology company that is reinventing healthcare, one employee at a time. It builds customized mobile and web experiences that connect company benefits and incentives design to healthy employee behaviors using the wearables and apps that they all know and love.The company was founded in 2010 and isheadquartered in Mountain View, California. | $23.3M / Series C / May 21, 2015 | |
Curetis
|
Curetis AG focuses on multiparameter testing of many analytes in a single run, providing broad panels of combined pathogen and resistance gene detection for a wide range of diseases.Curetis integrates today´s molecular diagnostics laboratory into one instrument for the detection of severe bacterial infections as a first target application.However, the universal platform will also allow the future expansion into other clinical applications with additional market opportunities beyond infectious diseases. | $15.9M / Series B / Nov 20, 2014 | |
|
Jiff
|
Jiff is a venture-backed, Mountain View-based technology company that is reinventing healthcare, one employee at a time. It builds customized mobile and web experiences that connect company benefits and incentives design to healthy employee behaviors using the wearables and apps that they all know and love.The company was founded in 2010 and isheadquartered in Mountain View, California. | $18.3M / Series B / Sep 23, 2014 | |
Affimed
|
At Affimed, they are committed to improving outcomes for patients with cancer. Their scientific team has been devoted to unlocking the power of the innate immune system for nearly two decades to provide a unqiue approach to fighting cancer. With their unparalleled expertise in innate immunity and innate cell engager-based medicines, they aim toovercome the limitations and challenges faced by current immuno-oncology (I-O) therapies. | $15.7M / Series E / Sep 02, 2014 | |
Smaato
|
Smaato’s Digital Advertising Technology Platform gives publishers the controls to deliver seamless, tailored, and engaging experiences for their audiences and advertisers. Advanced targeting capabilities and competitive intelligence help publishers optimize their monetization strategy to create data-driven experiences and reach their full revenuepotential. Founded in 2005, Smaato is headquartered in San Francisco, California, with additional offices in Hamburg, New York, Shanghai, Beijing, and Singapore. Learn more at www.smaato.com. | $25M / Series E / Aug 05, 2014 | |
GenomeDx Biosciences
|
GenomeDx discovers, develops, and commercializes genomic-based laboratory tests for the personalized medicine revolution in cancer care. In partnership with physicians and scientists from leading academic medicine institutions, our mission is to bring cost-effective and high-resolution genomics for routine clinical use in cancer medicine. | Series B / Sep 30, 2013 | |
Solstice Biologics
|
Solstice Biologics is a biotech company that provides solutions for targeting and delivering nucleic acid therapeutics. The Company specializes in the development of small, cell-permeable RNAi pro-drugs that can enter many different cell types and deliver on the promise of RNAi therapeutics.It was established in 2012 and is based in SanFrancisco, California. | $18M / Series A / Jan 04, 2013 | |
Crescendo Bioscience
|
Crescendo Bioscience, Inc. develops quantitative and objective diagnostic tools to provide rheumatologists with clinical insights to manage patients with autoimmune and inflammatory diseases. It provides diagnostic, prognostic, staging, therapy selection, and monitoring facilities to physicians. Crescendo Bioscience, Inc. was formerly known asRiley Genomics, Inc. The company was founded in 2002 and is based in South San Francisco, California. | $28M / Series D / Jan 03, 2013 | |
|
Solstice Biologics
|
Solstice Biologics is a biotech company that provides solutions for targeting and delivering nucleic acid therapeutics. The Company specializes in the development of small, cell-permeable RNAi pro-drugs that can enter many different cell types and deliver on the promise of RNAi therapeutics.It was established in 2012 and is based in SanFrancisco, California. | $7.5M / Private Equity / Dec 28, 2012 | |
| See all 22 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Aeris Capital invest in?
Aeris Capital invests primarily in Biotechnology, Medical and Health Care startups, most often at Series A and Series D stage. Most of the 22 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Aeris Capital?
Public channels for Aeris Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Aeris Capital?
The team at Aeris Capital includes George Rehm (Managing Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
